Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine
Oral Science International · 2019
DOI: 10.1002/osi2.1006 ↗Abstract
Abstract Cutaneous lupus erythematosus ( CLE ) is a rare, potentially disfiguring, chronic autoimmune disease with extremely variable skin and mucosal membrane manifestations. Hydroxychloroquine ( HCQ ) is an antimalarial drug that has been used in various countries to treat autoimmune diseases including CLE . HCQ was banned for a long time in Japan because of severe chloroquine retinopathy and was reapproved as a first‐line treatment for CLE in 2015. There are no case reports describing the effectiveness of HCQ for CLE with oral mucosal lesions in the dental field. We present a case of CLE whose oral lesions were successfully treated with HCQ .
EUVIMED